Edgewise Therapeutics locks in $50 mln Series B

Boulder, Colorado-based Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, has secured $50 million in Series B financing. Novo Holdings A/S and U.S. Venture Partners led the round.

North AmericaUSHealthcareBriefs